Daiwa Securities Group Inc. Has $1.46 Million Stock Holdings in Jazz Pharmaceuticals PLC $JAZZ

Daiwa Securities Group Inc. grew its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 274.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 8,583 shares of the specialty pharmaceutical company’s stock after buying an additional 6,292 shares during the period. Daiwa Securities Group Inc.’s holdings in Jazz Pharmaceuticals were worth $1,459,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in JAZZ. Royal Bank of Canada increased its stake in shares of Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock valued at $8,394,000 after buying an additional 33,210 shares during the period. Goldman Sachs Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after buying an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares during the period. Focus Partners Wealth increased its stake in shares of Jazz Pharmaceuticals by 3.4% in the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares during the period. Finally, Geneos Wealth Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 57.6% in the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 137 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on JAZZ. Truist Financial set a $256.00 price target on Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday. Bank of America increased their price target on Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday. TD Cowen increased their price target on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Weiss Ratings raised Jazz Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, May 26th. Finally, Raymond James Financial reiterated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Sixteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $246.06.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $229.63 on Thursday. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $243.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The business’s 50 day moving average price is $215.82 and its two-hundred day moving average price is $188.13. The firm has a market cap of $14.43 billion, a PE ratio of -11,475.76, a price-to-earnings-growth ratio of 0.22 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.59 EPS for the current year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $241.57, for a total value of $662,143.37. Following the transaction, the director owned 9,567 shares in the company, valued at approximately $2,311,100.19. This represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bruce C. Cozadd sold 6,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director owned 384,682 shares in the company, valued at approximately $73,281,921. The trade was a 1.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 10,741 shares of company stock valued at $2,287,143. 4.30% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.